CPTH2

• Description:

  CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) [1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Histone Acetyltransferase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cpth2.html

• Purity:

  99.82

• Solubility:

  DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 1 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC=C(C2=CSC(N/N=C3CCCC/3)=N2)C=C1

• Molecular Formula:

  C14H14ClN3S

• Molecular Weight:

  291.80

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Cocco E, et al. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumoraggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics. 2018 Apr 4;10:44.|[2]Chimenti F, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4- (4'-chlorophenyl) thiazol-2-yl) hydrazone. J Med Chem. 2009 Jan 22;52 (2) :530-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  GCN5/PCAF

• CAS Number:

  [357649-93-5]